Endorsement for antibody test

The rapid COVID-19 antibody detection test developed by Bondholder SureScreen Diagnostics has received a resounding endorsement.

Experts at Guy’s and St. Thomas’s Hospital and Kings College University in London, which treated Prime Minister Boris Johnson, have been comparing the accuracy of tests from different companies and have published data which shows SureScreen’s performed outstandingly in critical areas.

The study illustrates how important quality antibody testing is for combatting COVID-19. If used in mass testing, it could be vital in showing how many people had contracted the virus and lead to a better understanding of potential immunity.

The Derbyshire-based company has been involved in diagnostic healthcare testing for a quarter of a century and has built up a reputation for quality worldwide.

It developed its ten-minute COVID-19 test within weeks of the outbreak in Wuhan. Since then, millions of its tests have been used in Germany, Spain, Italy, Norway, Sweden, Switzerland, South Africa, Peru and Panama.

The President of Portugal, Marcelo Rebelo de Sousa, recently took the SureScreen test which confirmed he had not had the virus.

SureScreen’s Director, David Campbell, said: “Our test detects two key antibodies which are created by the body in response to COVID-19 infection; known as IgG and IgM.

“The test can be used quickly in 10 minutes at the patient side, without the need to wait on results from the laboratory. It is perfect for use in a hospital setting, or longer-term to identify if someone has built up antibodies from a previous infection.

“We hope that the test can be used within the NHS to help the fight against this pandemic.”